Jonathan Kay to Drug Industry
This is a "connection" page, showing publications Jonathan Kay has written about Drug Industry.
Connection Strength
0.227
-
Kay J, Feagan BG, Guirguis MS, Keystone EC, Klein AV, Lubiniecki AS, Mould DR, Nyarko KA, Ridgway AA, Trudeau ME, Wang J. Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012. Biologicals. 2012 Nov; 40(6):517-27.
Score: 0.100
-
Kay J. Biosimilars: a regulatory perspective from America. Arthritis Res Ther. 2011 May 12; 13(3):112.
Score: 0.091
-
Bridges SL, White DW, Worthing AB, Gravallese EM, O'Dell JR, Nola K, Kay J, Cohen SB. The Science Behind Biosimilars: Entering a New Era of Biologic Therapy. Arthritis Rheumatol. 2018 03; 70(3):334-344.
Score: 0.036